Defining statistical cure in patients with T1 high‐grade non‐muscle‐invasive bladder carcinoma treated with BCG immunotherapy
BJU International · 2026-02 · 137 (2) · 270-281
DOI: 10.1111/bju.16913 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 29.08.2025. Verfasst von José Daniel Subiela und 53 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Adjuvants, Immunologic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess cure fraction and conditional survival probabilities for oncological outcomes in patients with T1 high‐grade (T1HG) non‐muscle‐invasive bladder carcinoma (NMIBC) treated with adequate Bacillus Calmette‐Guérin (BCG) immunotherapy. Patients and Methods This multi‐institutional retrospective cohort study included 1403 patients with T1HG NMIBC treated between 2007 and 2020, adhering to modern guidelines including mandatory second transurethral resection of bladder tumour and adequate BCG, defined as at least five of six induction doses and at least two of three maintenance doses. Cure fraction, defined as the proportion of patients who will never experience the event of interest, was calculated for recurrence‐free survival (RFS), progression‐free survival (PFS), cancer‐specific survival (CSS) and overall survival (OS) using a mixture cure model. Conditional survival probabilities over 5 years were also computed.
Results
Cure fractions were 41% (95% confidence interval [CI] 36%–46%) for RFS, 71% (95% CI 65%–76%) for PFS, 76% (95% CI 70%–83%) for CSS, and 38% (95% CI 28%–49%) for OS. Patients in very‐high‐risk subgroups, according to the European Association of Urology risk stratification, showed significantly lower cure fractions, particularly for PFS (61% [95% CI 50%–72%]) and CSS (59% [95% CI 34–84%]). Conditional survival analysis demonstrated that patient prognoses improved over time, with 5‐year conditional RFS, PFS, CSS and OS probabilities exceeding 90% for patients who were event‐free at 5 years from diagnosis.
Conclusions
We found that BCG immunotherapy achieves a statistical cure in select T1HG NMIBC patients, with avoidance of progression to muscle‐invasive bladder carcinoma in approximately 70% of cases. The probability of experiencing any adverse oncological event (recurrence, progression or death) is less than 10% among patients who remain event‐free for 5 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain.
- Department of Urology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck, Austria.
- Department of Minimally Invasive Robotic Urology, Center of Excellence in Urology, Wrocław Medical University, Wrocław, Poland.
- Department of Urology, Clínica Universidad de Navarra, Madrid, Spain.
- Servicio de Urología, Hospital Universitario Rey Juan Carlos, Universidad Rey Juan Carlos Móstoles, Madrid, Spain.
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
ORCID-Profile: José Daniel Subiela, Alberto Artiles Medina, Renate Pichler, Daniel A González-Padilla, Keiichiro Mori, Mario de Angelis, Roberto Contieri, Andrea Gallioli, David D'Andrea, Jeremy Yuen-Chun Teoh, Francesco Del Giudice, Simone Albisinni, Francesco Soria, Laura S Mertens, Ekaterina Laukhtina, Karl Tully, Andrea Mari, Marco Moschini, Ana Saiz
Zitieren
APA
Subiela, J. D., de la Parra, I., Taborda, J., Medina, A. A., Pichler, R., Krajewski, W., Ojeda, C. M., Mardomingo, A. F., Durán, P. D. O., Pérez, E. L., González-Padilla, D. A., Aumatell, J., Mori, K., Scilipoti, P., Longoni, M., de Angelis, M., Caño-Velasco, J., Puentedura, A. L., Pujol, L. P., …, & From Young Academic Urologist: Urothelial Carcinoma Working Group (2026). Defining statistical cure in patients with T1 high‐grade non‐muscle‐invasive bladder carcinoma treated with BCG immunotherapy. BJU International, 137(2), 270-281. https://doi.org/10.1111/bju.16913
Vancouver
Subiela JD, de la Parra I, Taborda J, Medina AA, Pichler R, Krajewski W, et al. Defining statistical cure in patients with T1 high‐grade non‐muscle‐invasive bladder carcinoma treated with BCG immunotherapy. BJU International. 2026;137(2):270-281. doi:10.1111/bju.16913
BibTeX
@article{Subiela2026,
author = {Subiela, José Daniel and de la Parra, Irene and Taborda, Javier and Medina, Alberto Artiles and Pichler, Renate and Krajewski, Wojciech and Ojeda, Cesar Mínguez and Mardomingo, Ana Fernández and Durán, Pedro Del Olmo and Pérez, Enrique López and González-Padilla, Daniel A and Aumatell, Júlia and Mori, Keiichiro and Scilipoti, Pietro and Longoni, Mattia and de Angelis, Mario and Caño-Velasco, Jorge and Puentedura, Alfonso Lafuente and Pujol, Lucia Polanco and Contieri, Roberto and Gallioli, Andrea and Tukiendorf, Andrzej and D'Andrea, David and Teoh, Jeremy Yuen-Chun and Afferi, Luca and Del Giudice, Francesco and Marcq, Gautier and Albisinni, Simone and Soria, Francesco and Mertens, Laura S and Laukhtina, Ekaterina and Tully, Karl and Mari, Andrea and Guerrero-Ramos, Félix and Alvarez-Maestro, Mario and Martín, Carlos Casanova and Melendres, Franklin Anagua and Buisan, Oscar and López-González, José Agustín and Dominguez-Escrig, José Luis and Aranda, Javier and Elena, José Luis Rodríguez and Basile, Giuseppe and Santos, Victoria Gómez Dos and Moschini, Marco and Pradere, Benjamin and Acosta, Eduardo Albers and Palacio, Fernando Lozano and Puig, Albert Carrión and Gajate, Pablo and Saiz, Ana and Gontero, Paolo and Revilla, Francisco Javier Burgos and From Young Academic Urologist: Urothelial Carcinoma Working Group, From Young Academic Urologist: Urothelial Carcinoma Working Group},
title = {Defining statistical cure in patients with T1 high‐grade non‐muscle‐invasive bladder carcinoma treated with BCG immunotherapy},
journal = {BJU International},
year = {2026},
volume = {137},
number = {2},
pages = {270--281},
doi = {10.1111/bju.16913}
}
EUVIMED